000963 华东医药
已收盘 09-30 15:00:00
资讯
新帖
简况
华东医药（000963）披露2026年半年度报告，9月30日股价上涨3.13%
证券之星 · 09-30 17:27
华东医药（000963）披露2026年半年度报告，9月30日股价上涨3.13%
华东医药：创新药收入占医药工业营收比重达到50%为公司争取达成的阶段性努力方向
证券之星 · 09-30 15:37
华东医药：创新药收入占医药工业营收比重达到50%为公司争取达成的阶段性努力方向
华东医药：HDM1002片是公司内分泌/代谢赛道重点自研创新品种
证券之星 · 09-29 16:48
华东医药：HDM1002片是公司内分泌/代谢赛道重点自研创新品种
华东医药：创新产品业务收入占比将稳步提升
证券之星 · 09-29 16:45
华东医药：创新产品业务收入占比将稳步提升
华东医药：HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品
证券之星 · 09-29 16:39
华东医药：HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品
华东医药：HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势
证券之星 · 09-29 16:36
华东医药：HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势
华东医药HDM1002片取得顶线结果 未来商业化价值几何？
新浪证券 · 09-29 09:36
华东医药HDM1002片取得顶线结果 未来商业化价值几何？
华东医药：HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析
证券之星 · 09-28
华东医药：HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析
华东医药最新公告：全资子公司创新GLP-1靶点口服小分子激动剂HDM1002片减重Ⅲ期研究获得积极顶线结果
证券之星 · 09-27
华东医药最新公告：全资子公司创新GLP-1靶点口服小分子激动剂HDM1002片减重Ⅲ期研究获得积极顶线结果
华东医药：工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局
证券之星 · 09-24
华东医药：工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局
华东医药加快再生医美布局，欣可丽美学独家合作引入ECM胶原蛋白MB007
中金财经 · 09-17
华东医药加快再生医美布局，欣可丽美学独家合作引入ECM胶原蛋白MB007
华东医药：目前和解谈判仍在推进过程中
证券之星 · 09-17
华东医药：目前和解谈判仍在推进过程中
华东医药：子公司半导体激光治疗仪注册申请获受理
智通财经 · 09-14
华东医药：子公司半导体激光治疗仪注册申请获受理
股市必读：华东医药新发布《2026年半年度权益分派实施公告》
证券之星 · 09-14
股市必读：华东医药新发布《2026年半年度权益分派实施公告》
华东医药（000963）披露2026年半年度权益分派实施公告，9月10日股价下跌1.33%
证券之星 · 09-10
华东医药（000963）披露2026年半年度权益分派实施公告，9月10日股价下跌1.33%
华东医药：积极推进炎朵®中国市场商业化供货事宜
证券之星 · 09-10
华东医药：积极推进炎朵®中国市场商业化供货事宜
瑞银：中国制药股上半年业绩好坏参半 首选先声药业
同花顺 · 09-09
瑞银：中国制药股上半年业绩好坏参半 首选先声药业
华东医药：依托四大业务推进长期发展
证券之星 · 09-09
华东医药：依托四大业务推进长期发展
华东医药：HDM1002体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出
证券之星 · 09-08
华东医药：HDM1002体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出
华东医药：已搭建人工智能辅助药物发现（AIDD）平台
证券之星 · 09-02
华东医药：已搭建人工智能辅助药物发现（AIDD）平台
加载更多
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":27.69,"timestamp":1790751789000,"preClose":26.85,"halted":0,"volume":32837967,"delay":0,"changeRate":0.0313,"floatShares":1753000000,"shares":1754000000,"eps":1.9731,"marketStatus":"已收盘","change":0.84,"latestTime":"09-30 15:00:00","open":26.73,"high":27.72,"low":26.69,"amount":903000000,"amplitude":0.0384,"askPrice":27.7,"askSize":812,"bidPrice":27.69,"bidSize":249,"shortable":0,"etf":0,"ttmEps":1.9731,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":26.85,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":29.54,"lowLimit":24.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.85,"roa":"--","peRate":14.033754,"roe":"7.31%","epsLYR":1.9484,"committee":-0.478988,"marketValue":48561000000,"turnoverRate":0.0187,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","floatMarketCap":48541000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2671270386","title":"华东医药（000963）披露2026年半年度报告，9月30日股价上涨3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270386","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671270386?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:27","pubTimestamp":1790760432,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，华东医药报收于27.69元，较前一交易日上涨3.13%，最新总市值为485.61亿元。该股当日开盘26.73元，最高27.72元，最低26.69元，成交额达9.03亿元，换手率为1.87%。华东医药于近日披露《2026年半年度报告（英文版）》。报告显示，报告期内公司实现营业总收入22,066,646,185.69元，同比增长1.81%；归属于上市公司股东的净利润为1,860,757,262.42元，同比增长2.53%；扣除非经常性损益后的净利润为1,857,546,440.75元，同比增长5.44%。经营活动产生的现金流量净额为2,499,419,530.63元，同比增长1.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000027365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","LU1969619763.USD","BK0196","000963","BK0132","BK0183","BK0209","BK0187","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279903","title":"华东医药：创新药收入占医药工业营收比重达到50%为公司争取达成的阶段性努力方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279903","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671279903?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:37","pubTimestamp":1790753859,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好 陈老师好 咱们公司工业板块规划《十五五》时 其中创新药大概什么时间营销占比能达到50%呢？您所提及的创新药收入占医药工业营收比重达到50%，为公司争取达成的阶段性努力方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000019744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671329784","title":"华东医药：HDM1002片是公司内分泌/代谢赛道重点自研创新品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2671329784","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671329784?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:48","pubTimestamp":1790671691,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月29日在投资者关系平台上答复投资者关心的问题。投资者提问：随着全球减重药市场从注射制剂逐步向口服制剂拓展，公司如何看待口服GLP-1未来在整个代谢药市场中的市场空间？HDM1002片是公司内分泌/代谢赛道重点自研创新品种，在整体创新药战略中占据重要地位。该产品减重适应症Ⅲ期已取得积极结果，降糖适应症正在同步推进Ⅲ期，是公司GLP-1差异化管线矩阵的重要一环。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU1969619763.USD","BK0196","000963","BK0132","LU2328871848.SGD","BK0188","BK0209","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297854","title":"华东医药：创新产品业务收入占比将稳步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297854","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671297854?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:45","pubTimestamp":1790671516,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月29日在投资者关系平台上答复投资者关心的问题。随着公司创新业务持续快速发展，创新产品业务收入占比将稳步提升。成熟业务作为公司经营基本盘，持续贡献稳定营收与经营性现金流，为创新研发投入提供坚实保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU1969619763.USD","BK0196","000963","BK0132","LU2328871848.SGD","BK0188","BK0209","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671292095","title":"华东医药：HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2671292095","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671292095?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:39","pubTimestamp":1790671148,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月29日在投资者关系平台上答复投资者关心的问题。投资者提问：目前公司围绕肥胖及代谢领域已经形成HDM1002、HDM1005、DR10624等多产品梯队，公司未来是否有意将代谢领域打造成为继消化、内分泌等优势领域之后新的核心增长平台？内分泌/代谢领域是公司医药工业的传统优势治疗领域，HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","000963","BK0132","BK0209","LU2328871848.SGD","LU1969619763.USD","BK0196","BK0175","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671229217","title":"华东医药：HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2671229217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671229217?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:36","pubTimestamp":1790670968,"startTime":"0","endTime":"0","summary":"投资者提问：随着HDM1002 III期临床取得积极结果并即将申报上市，未来HDM1002商业化后，公司对其销售放量有哪些核心优势？如后续HDM1002顺利获批上市，产品放量主要依托两大核心条件。二是HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势，作为每日一次口服小分子GLP-1激动剂，52 周治疗周期减重效果持续，未观察到减重平台期；除减重作用外，还可改善肝脏脂肪、优化体成分，保护瘦体重，多项心血管代谢指标同步获益；整体安全性良好，给药不受进食饮水限制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0209","BK0132","LU1969619763.USD","BK0175","LU2328871848.SGD","000963","BK0188","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671617312","title":"华东医药HDM1002片取得顶线结果 未来商业化价值几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2671617312","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671617312?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:36","pubTimestamp":1790645760,"startTime":"0","endTime":"0","summary":"近日，华东医药发布公告称，其全资子公司中美华东自主研发的1类创新药、口服小分子GLP-1受体激动剂HDM1002片用于超重或肥胖人群体重管理的中国Ⅲ期临床研究取得积极顶线结果，已完成Pre-NDA沟通，即将正式递交上市申请。作为华东医药内分泌代谢赛道的核心创新品种，HDM1002的临床进展与商业化潜力一直是资本市场关注焦点。患者总人数方面，HDM1002核心覆盖具备药物减重治疗指征的超重与肥胖人群。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-29/doc-initmzhp3097769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000963","BK0196","BK0187","BK0175","BK0188","LU1969619763.USD","BK0132","BK0183","LU2328871848.SGD","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670803842","title":"华东医药：HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2670803842","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670803842?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:33","pubTimestamp":1790584387,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)09月28日在投资者关系平台上答复投资者关心的问题。投资者提问：HDM1005 体重管理 III 期 40 周数据是否已读出？预计何时、以何种方式对外披露？华东医药回复：您好！HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800021309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0188","000963","BK0196","BK0209","LU2328871848.SGD","BK0132","BK0183","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670408002","title":"华东医药最新公告：全资子公司创新GLP-1靶点口服小分子激动剂HDM1002片减重Ⅲ期研究获得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2670408002","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670408002?lang=zh_cn&edition=full","pubTime":"2026-09-27 16:19","pubTimestamp":1790497177,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司中美华东自主研发的1类创新药HDM1002片用于超重或肥胖人群体重管理的中国Ⅲ期临床研究取得积极顶线结果。研究显示，各剂量组第44周达到全部主要终点与关键次要终点，第52周体重较基线平均下降10.7%与12.2%，未观察到减重平台期。同时观察到肝脏脂肪含量大幅降低、体成分优化及多项心血管代谢指标改善，安全性特征良好。公司已完成Pre-NDA沟通，即将正式递交上市申请。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092700001023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","LU1969619763.USD","BK0196","BK0188","LU2328871848.SGD","BK0132","000963","BK0183","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669845749","title":"华东医药：工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2669845749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669845749?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:21","pubTimestamp":1790234468,"startTime":"0","endTime":"0","summary":"公司工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局，强化技术创新迭代与海内外市场拓展，将深度融入全球医药供应链作为现阶段核心工作目标，海内外重点客户开发取得阶段性成效。今年上半年，公司工业微生物海外业务销售增长33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400021376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU2328871848.SGD","BK0175","BK0209","BK0132","000963","BK0183","BK0196","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668495968","title":"华东医药加快再生医美布局，欣可丽美学独家合作引入ECM胶原蛋白MB007","url":"https://stock-news.laohu8.com/highlight/detail?id=2668495968","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668495968?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:10","pubTimestamp":1789636203,"startTime":"0","endTime":"0","summary":"2026年9月17日，华东医药股份有限公司宣布，其全资子公司欣可丽美学(杭州)医疗科技有限公司与北京美柏医药生物技术发展有限公司及湖南美柏生物医药有限公司正式签署战略合作协议，就细胞外基质胶原蛋白MB007产品在中国市场达成独家战略合作。 此次合作是华东医药在再生医美材料领域从传统填充向新型生物材料源头延伸的关键一步，也标志着公司在ECM胶原蛋白这一前沿赛道完成战略卡位。目前，美柏生物正在全力推进MB007的III期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260917/32373220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0132","LU1969619763.USD","000963","LU2328871848.SGD","BK0188","BK0196","BK0209","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668950970","title":"华东医药：目前和解谈判仍在推进过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2668950970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668950970?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:42","pubTimestamp":1789634531,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月17日在投资者关系平台上答复投资者关心的问题。你所说的“针对前期延迟供货对应的和解事，双方经协商已取得积极进展，并将积极推进中国市场商业化供货事宜。”请问，和解协议何时能签，炎朵何时能在国内上市？目前和解谈判仍在推进过程中，尚未正式完成协议签署。公司正全力推动各项工作，力争尽快落实和解相关安排，推进中国市场商业化供货事宜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700025833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0183","BK0187","BK0175","BK0209","LU2328871848.SGD","000963","BK0132","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667575786","title":"华东医药：子公司半导体激光治疗仪注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667575786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667575786?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:11","pubTimestamp":1789380697,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["000963","BK0209","BK0175","BK0132","LU1969619763.USD","BK0183","BK0196","LU2328871848.SGD","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680219","title":"股市必读：华东医药新发布《2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680219","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680219?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:32","pubTimestamp":1789324333,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，华东医药报收于26.26元，下跌1.35%，换手率0.58%，成交量10.2万手，成交额2.67亿元。公司公告汇总：华东医药将于2026年9月18日实施2026年半年度权益分派，每10股派发现金红利3.50元（含税），合计派发613,807,896.80元（含税）。股权登记日为2026年9月17日，除息日和红利发放日均为2026年9月18日。本次权益分派对象为截至股权登记日在册的全体A股股东。公司计划在数据就绪后推进相关披露工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400001010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0183","BK0187","BK0175","BK0209","LU2328871848.SGD","000963","BK0132","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666913145","title":"华东医药（000963）披露2026年半年度权益分派实施公告，9月10日股价下跌1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666913145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666913145?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:09","pubTimestamp":1789049357,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，华东医药报收于26.62元，较前一交易日下跌1.33%，最新总市值为466.84亿元。该股当日开盘26.88元，最高26.89元，最低26.6元，成交额达2.4亿元，换手率为0.51%。近日，华东医药股份有限公司发布《2026年半年度权益分派实施公告》。股权登记日为2026年9月17日，除息日和红利发放日均为2026年9月18日。本次权益分派对象为截至股权登记日在册的全体A股股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000041888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0132","LU1969619763.USD","000963","LU2328871848.SGD","BK0188","BK0196","BK0209","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666855615","title":"华东医药：积极推进炎朵®中国市场商业化供货事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2666855615","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666855615?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:51","pubTimestamp":1789001467,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问：利纳西普获批近两年了，迟迟没有上市销售，公司采取了哪些措施？有哪些进步？还有希望吗？华东医药回复：您好！公司持续与合作方对接炎朵产品供货事宜。针对前期延迟供货对应的和解事项，双方经协商已取得积极进展，并将积极推进中国市场商业化供货事宜。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0196","BK0175","LU1969619763.USD","LU2328871848.SGD","BK0187","BK0209","BK0183","BK0132","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831405","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831405","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831405?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:58","pubTimestamp":1788940680,"startTime":"0","endTime":"0","summary":"瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药(03692)、先声药业(02096)、中国生物制药(01177)、石药集团(01093)及科伦 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260909/c679739404.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260909/c679739404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0196","BK0239","BK0183","LU1064131003.USD","BK0175","000963","BK0188","002422","LU1064130708.USD","LU1969619763.USD","BK0187","BK0209","BK0132","LU1979443071.USD","LU2148510915.USD","BK0060","LU2328871848.SGD","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666246583","title":"华东医药：依托四大业务推进长期发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2666246583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666246583?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:54","pubTimestamp":1788940450,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月09日在投资者关系平台上答复投资者关心的问题。公司依托医药工业、医药商业、医美、工业微生物四大业务推进长期发展：医药工业坚持创新驱动，优化研发管理，持续推进创新药研发与商业化；医药商业向综合药事服务商转型，拓宽非药、代理及分销业务；医美加快海内外产品注册，强化品牌建设与学术推广，持续为求美者提供综合解决方案；工业微生物聚焦大品种，降本增效，拓展海外市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900023501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","LU1969619763.USD","BK0209","BK0188","BK0175","BK0132","BK0196","BK0187","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373996","title":"华东医药：HDM1002体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373996","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665373996?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:52","pubTimestamp":1788871927,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月07日在投资者关系平台上答复投资者关心的问题。华东医药多款创新药即将亮相 EASD、EADV 与 ESMO 2026 年会。在这些展示的创新产品中并未提及HDM1002,我想问的是因为三期数据没有读出，所以不参展？HDM1002，体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出，后续52周治疗及4周安全随访数据预计今年9月完成，计划今年Q4递交NDA申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800034484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","000963","BK0132","BK0209","LU2328871848.SGD","LU1969619763.USD","BK0196","BK0175","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664937898","title":"华东医药：已搭建人工智能辅助药物发现（AIDD）平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2664937898","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664937898?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:48","pubTimestamp":1788320887,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月01日在投资者关系平台上答复投资者关心的问题。公司已搭建人工智能辅助药物发现平台，并持续深化在新药研发中的落地应用，推动 AI、生物信息学与研发流程深度融合，赋能靶点评估、分子设计、候选化合物筛选、成药性优化等环节。目前 AIDD 团队已支持近30个在研项目。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200017684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0188","000963","BK0196","BK0209","LU2328871848.SGD","BK0132","BK0183","161631","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790851694158,"stockEarnings":[{"period":"1week","weight":0.0449},{"period":"1month","weight":0.0296},{"period":"3month","weight":-0.0483},{"period":"6month","weight":-0.2102},{"period":"1year","weight":-0.3102},{"period":"ytd","weight":-0.2735}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100196人(较上一季度增加18.85%)","perCapita":"17495股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}